Table 1

Clinical outcome in 12 canine carcinoma patients treated with BR96 sFv-PE40

CaseCarcinoma typeConcurrent immunosuppressive therapyDosage (mg/m2)No. dosesResponseNo. doses before antibodies developedSurvival (d)
1Inflammatory mammaryNone6 (2)6SD557
12 (4)
2TonsilNone1210PR3232
3Inflammatory mammaryNone122PR2233 (30 on study)
4BiliaryNone128PD5236 (40 on study)
5RectalNone93SD234
6Inflammatory mammaryNone122.5SD2186
7LungDexamethasone42.5PR252
8LungDexamethasone123PD2148
9RectalDexamethasone64SD3173
10Urinary bladderDexamethasone45PDNA164
11NasalCTLA4-Ig49PD272
12Lacrimal glandCTLA4-Ig43PD2854
  • Abbreviations: PD, progressive disease; SD, stable disease; PR, partial remission; NA, not available.